To The Moon

$UiPath(PATH)$ is scheduled to report its fiscal fourth-quarter 2026 results on Wednesday, March 11, 2026, after the market closes. The company is currently in a transitional phase, moving from traditional Robotic Process Automation (RPA) toward "agentic" AI-driven automation.

Earnings Expectations (Q4 FY2026)

Wall Street expectations have remained relatively stable leading up to the report:

Revenue: Consensus estimate is $464.86 million, representing approximately 9.7% year-over-year growth.

Non-GAAP EPS: Analysts are projecting $0.25, a slight decline from the $0.26 reported in the same quarter last year.

Prior Performance: UiPath has a history of beating both revenue and EPS estimates. In Q3 2026, they delivered a revenue beat of nearly 5% and an EPS beat of 6.67%.

UiPath’s fiscal Q3 2026 earnings, reported on December 3, 2025, were widely viewed as a "turnaround" quarter. The company moved past previous execution issues and proved it could maintain profitability while integrating AI into its core product suite.

Fiscal Q3 2026 Financial Highlights

• Revenue: $411.1 million (up 16% YoY), beating the analyst consensus of ~$392 million.

• Non-GAAP EPS: $0.16, surpassing the estimated $0.14.

• Profitability Milestone: For the first time in three years, UiPath achieved GAAP profitability with a net income of $13 million.

• Annual Recurring Revenue (ARR): Reached $1.782 billion (up 11% YoY), driven by $59 million in "Net New ARR."

• Net Retention Rate (NRR): Logged at 107%, showing slight compression from the previous year (~110%) but stabilizing.

The "Lesson Learnt" from Guidance

The most critical takeaway from the Q3 earnings call—and the subsequent market reaction—centered on the cautious but disciplined outlook for Q4 and beyond.

1. Conservatism is the New Playbook

Management raised Q4 revenue guidance to $462M–$467M, but analysts noted the midpoint was effectively "in-line" with broader expectations rather than a massive breakout.

• Lesson: After the volatility seen in early FY2025, management has shifted to a "under-promise and over-deliver" strategy. Investors now value execution stability over aggressive, risky growth targets.

2. The "Agentic AI" Gap

While CEO Daniel Dines highlighted that over 950 companies are now developing AI agents on the platform, he explicitly stated that there would be no material revenue contribution from AI agents until FY2027.

• Lesson: There is a "transition gap" between AI hype and AI revenue. Investors learned that while UiPath is successfully pivoting to "Agentic Automation" (using LLMs to handle complex tasks), the financial impact lags behind the technical implementation.

3. Efficiency Over "Growth at All Costs"

The guide for $140 million in non-GAAP operating income for Q4 signaled a commitment to margin expansion.

• Lesson: UiPath has successfully transitioned from a "hyper-growth" cash-burner to a mature software firm. The market rewarded the 21% operating margin, indicating that in the current high-interest-rate environment, profitable 15% growth is more attractive than unprofitable 25% growth.

Summary for Investors

The Q3 results effectively removed the "bear case" that UiPath would be made obsolete by LLMs. Instead, the guidance suggests a steady-state business that is using its $1.5 billion cash pile to bridge the gap until its new AI products (like Maestro and Autopilot) hit full commercial scale next year.

Key Metrics to Watch

Beyond the top and bottom lines, investors will focus on the health of the subscription model and the early adoption of AI features.

UiPath (PATH) Price Target

Based on 16 analysts from Tiger Brokers app offering 12 month price targets for UiPath in the last 3 months. The average price target is $16.17 with a high forecast of $19.00 and a low forecast of $13.88. The average price target represents a 35.05% change from the last price of $11.97.

Short-Term Trading Analysis

The stock has shown significant volatility leading into this event, rebounding from a recent six-day losing streak to trade around $11.85 (as of March 6).

• Bull Case: A "beat and raise" scenario where management provides FY2027 guidance above $1.65 billion and highlights strong traction with their new Agentic AI platform. The average analyst price target is $15.77, suggesting significant upside if the market re-rates the stock as an "AI winner."

• Bear Case: Continued compression in NRR and cautious guidance due to longer enterprise sales cycles for AI products. Recent insider selling by the CEO and CFO (totaling ~$15.9M over 90 days) has also created a slight overhang on sentiment.

• The "Wheel" Potential: Given the current low share price relative to historical levels and a debt-free balance sheet with $1.4 billion in cash, the stock may attract traders looking to sell cash-secured puts if IV (Implied Volatility) spikes before the 11th.

Technical Analysis - Exponential Moving Average (EMA)

We have seen a pretty strong recovery from PATH, it has managed to move to trade above the 50-day period, could this be an indication that there is strong traction with their new Agentic AI platform?

But the AI spending fears due to longer enterprise sales cycles for AI products might have investors thinking whether PATH could continued to show potential, but if PATH could continue to provide strong guidance and also provide data showing strong traction on their new Agentic AI platform, we could see a significant buying volume which could popped up the share price for PATH.

Summary

UiPath (PATH) is scheduled to release its fiscal Q4 2026 earnings on Wednesday, March 11, 2026, after the market closes. This report is viewed as a pivotal "gut check" for the company's transition into an AI-first agentic automation platform.

Financial Expectations

Wall Street analysts are looking for a steady performance, though year-over-year comparisons remain tough:

• Revenue: Consensus is $464.9 million, implying ~10% growth.

• Non-GAAP EPS: Projected at $0.25, a slight 4% decline from the previous year.

• ARR: Investors are targeting a total of $1.85 billion, which would reflect roughly 11% growth.

Key Metrics to Watch

The market’s reaction will likely hinge on underlying health indicators rather than just the headline numbers:

• Net Retention Rate (NRR): Analysts expect NRR to land around 107%. Any further compression below this level could signal competitive pressure or slower enterprise expansion.

• Fiscal 2027 Guidance: This is the primary catalyst. Since management previously stated that "agentic AI" wouldn't materially contribute to the top line until FY27, investors are desperate for a growth re-acceleration forecast.

• Subscription Growth: Look for the "Subscription Services" line (expected at $251 million) to outpace legacy license revenue, confirming the successful shift to a SaaS-heavy model.

Market Sentiment & Trading Outlook

UiPath enters this print with mixed momentum. While the stock has rebounded recently to around $11.85, it has been a laggard compared to the broader tech sector, falling ~37% over the last three months.

• The Bull Case: A "beat and raise" scenario where FY27 guidance exceeds $1.65 billion, potentially driving shares toward the average analyst price target of $15.77.

• The Bear Case: Cautious guidance and heavy insider selling (nearly $16 million over the last 90 days) remain a concern for short-term traders.

Given the stock's $1.4 billion cash pile and lack of debt, it remains a fundamental favorite for those betting on the "unsexy" side of AI—back-office automation—but the burden of proof lies on management to show that their new AI agents are winning over customers today.

Appreciate if you could share your thoughts in the comment section whether you think PATH could provide a stronger ARR on the back of strong tractions in PATH’s new Agentic AI platform.

@TigerStars @Daily_Discussion @Tiger_Earnings @TigerWire @MillionaireTiger appreciate if you could feature this article so that fellow tiger would benefit from my investing and trading thoughts.

Disclaimer: The analysis and result presented does not recommend or suggest any investing in the said stock. This is purely for Analysis.